The representation of BioCubaFarma and the Russian Company Alphanil signed last Wednesday a co-development agreement to expand the research of an innovative product against cancer.

Adolfo Castillo, technical scientific attaché of the Cuban Group of Biotechnological and Pharmaceutical Industries, told Prensa Latina that the Center of Molecular Immunology of the Caribbean Island will be the leading institution of the project on the Cuban side.

On the subject, he added that it responds to the objectives of this organization to establish alliances with Russian developers in the sector to achieve joint products that can be registered and applied for the benefit of this country and other nations in the Eurasian region.

According to a note published in Cubadebate, the director of the Russian Company Alphanil, Dimitri Chevlosky, pointed out that this innovation comes after the success of a similar one dedicated to the treatment of Parkinson´s disease.

He stressed out that the new product is in the middle of the preclinical stage and is being developed by the Antillean part of the Center of Research and development of Medicine(Cidem) and by Russia with Neyros.

The Russian directive detailed that the new immunotherapy against cancer will get to the development stage on 2022, under the aim of starting its clinical trials on 2025.

Both projects, which have already become companies, are located in the Skolkovo Innovation Center, a space for the promotion of science and technology, ranked as one of the largest of its kind in Europe.

Skolkovo is a fundamental scenario for BioCubaFarma since it has serve as a platform to exhibit the wide portfolio of products and services they have, including several drugs already registered in Kazakhstan, Belarus, China and India, among others.

Taken from ACN